Anh Dinh, MD

MD, Eastern Virginia Medical School
BA, University of Virginia

Dr. Dinh received her BA in Biology from the University of Virginia and her MD from Eastern Virginia Medical School. She completed her clinical pathology residency at Beth Israel Deaconess Medical Center / Harvard Medical School, where she served as Chief Resident. She then completed fellowship training through the Harvard Medical School Fellowship Program in Transfusion Medicine and the Children’s Hospital of Philadelphia (CHOP) Histocompatibility and Immunogenetics Fellowship Program. She subsequently served as an Assistant Director of the CHOP Immunogenetics laboratory and Assistant Professor of Pathology and Laboratory Medicine at the Perelman School of Medicine, University of Pennsylvania. She is board-certified in clinical pathology and blood banking/transfusion medicine and is an Affiliate of the American College of Histocompatibility and Immunogenetics.

Dr. Dinh currently serves as the Associate Medical Director and Chief of the Research Practice Development (RPD) team in the Center for Cellular Engineering (CCE) in the Department of Transfusion Medicine of the Clinical Center at the NIH. The CCE processes standard cell therapies for transplantation and manufactures advanced cell and gene therapies, including virus-specific T-cells, gene-modified hematopoietic stem cells, chimeric antigen receptor T-cells, and T-cell receptor engineered T-cells, for patients treated on research protocols at the NIH Clinical Center. Dr. Dinh serves as the medical liaison and clinical consultant for clinical issues related to cell therapies processed or manufactured in the CCE.

Dr. Dinh has published in peer-reviewed journals and textbooks on various topics related to transfusion medicine, histocompatibility, and cell therapies. Her research interests include the application of advanced methodologies for cell therapy product characterization, non-viral methods for cell therapy engineering, and optimized logistics of off-site manufactured cell therapy products.

• Second and Third Year Science Scholar University of Virginia, 2007-2009
• Fellow Teaching Award, Beth Israel Deaconess Medical Center, Harvard Medical School, 2018
• Human Immunology Best Review Paper of 2021 Award, "Next-generation sequencing technologies: An overview," Senior Author, 2023
• NIH Clinical Center CEO Individual Award (Rising Star - Leader in the field of cellular therapies), 2024
• NIH Clinical Center CEO Group Award (Patient Care - Adoptive Cell Therapy Toxicity Management Team), 2024

Stroncek DF, Zhang N, Ren J, Somerville R, Dinh A. Expanding the reach of commercial cell therapies requires changes at medical centers. J Transl Med. 2024 Feb 19;22(1):181.

Dinh A, Stroncek DF. Healthcare center-based cell therapy laboratories supporting off-site manufactured cell therapies: The experiences of a single academic cell therapy laboratory. Transfusion. 2024 Feb;64(2):357-366.

Reddy OL, Sall MT, Dinh A, Cai Y, Ongkeko M, Arya N, Wilder J, Tran M, Jin P, Stroncek DF, Panch SR. Effects of extended transport on cryopreserved allogeneic hematopoietic progenitor cell (HPC) product quality and optimal methods to assess HPC stability. Transfusion 2023 Apr;63(4):774-781.

Ma J, Shao L, Fuksenko T, Liu H, Shi R, Dinh A, Highfill SL, Zhang N, Panch SR, Somerville RP, Stroncek DF, Jin P. Reference gene selection for clinical chimeric antigen receptor T-cell product vector copy number assays. Cytotherapy 2023 Mar 17 (23)00062-2.

Gedda MR, Danaher P, Shao L, Ongkeko M, Chen L, Dinh A, Thioye Sall M, Reddy OL, Bailey C, Wahba A, Dzekunova I, Somerville R, De Giorgi V, Jin P, West K, Panch SR, Stroncek DF. Longitudinal transcriptional analysis of peripheral blood leukocytes in COVID-19 convalescent donors. J Transl Med 2022 Dec 12;20(1):587.

Dinh A, Yoon EJ. Blood Group Systems and Pretransfusion Testing. Tietz Textbook of Laboratory Medicine, 7th ed., edited by Nader Rifai, et al., Elsevier, 2022.

Yoon EJ, Dinh A. Indications for Transfusion: RBCs, Platelets, Plasma, and Cryoprecipitate. Tietz Textbook of Laboratory Medicine, 7th ed., edited by Nader Rifai, et al., Elsevier, 2022.

Stroncek D, Dinh A, Rai H, Zhang N, Somerville R, Panch S. The need for uniform and coordinated practices involving centrally manufactured cell therapies. J Transl Med. 2022 Apr 25;20(1):184.

Hu T, Chitnis N, Monos D, Dinh A. Next-generation sequencing technologies: An overview. Hum Immunol. 2021 Nov;82(11):801-811. doi: 10.1016/j.humimm.2021.02.012.

Shieh M, Hayeck TJ, Dinh A, Duke JL, Chitnis N, Mosbruger T, Morlen RP, Ferriola D, Kneib C, Hu T, Huang Y, Monos DS. Complex Linkage Disequilibrium Effects in HLA-DPB1 Expression and Molecular Mismatch Analyses of Transplantation Outcomes. Transplantation. 2021 Mar 1;105(3):637-647.

Mosbruger TL, Dinou A, Duke JL, Ferriola D, Mehler H, Pagkrati I, Damianos G, Mbunwe E, Sarmady M, Lyratzakis I, Tishkoff SA, Dinh A, Monos DS. Utilizing nanopore sequencing technology for the rapid and comprehensive characterization of eleven HLA loci; addressing the need for deceased donor expedited HLA typing. Hum Immunol. 2020 Aug;81(8):413-422.

Huang Y, Dinh A, Heron S, Gasiewski A, Kneib C, Mehler H, Mignogno MT, Morlen R, Slavich L, Kentzel E, Frackelton EC, Duke JL, Ferriola D, Mosbruger T, Timofeeva OA, Geier SS, Monos D. Assessing the utilization of high-resolution 2-field HLA typing in solid organ transplantation. Am J Transplant. 2019 Jul;19(7):1955-1963.

Kaufman RM, Dinh A, Cohn CS, Fung MK, Gorlin J, Melanson S, Murphy MF, Ziman A, Elahie AL, Chasse D, Degree L, Dunbar NM, Dzik WH, Flanagan P, Gabert K, Ipe TS, Jackson B, Lane D, Raspollini E, Ray C, Sharon Y, Ellis M, Selleng K, Staves J, Yu P, Zeller M, Yazer M; BEST Collaborative. Electronic patient identification for sample labeling reduces wrong blood in tube errors. Transfusion. 2019 Mar;59(3):972-980.

Dinh A, Eliason K, Dzik WS. Time interval between antibody investigations among patients who demonstrate serial red cell antibody formation. Transfusion. 2019 Feb;59(2):738-743.